Can tumor hypoxia be turned into a chemotherapeutic advantage?;L'hypoxie tumorale peut-elle devenir un avantage pour la chimiothérapie?

Bulletin du Cancer

Volumn 95, Issue 5, 2008, Pages 528-534

  Trédan, Olivier ^a   Grantab, Rama ^b   Dumontet, Charles ^c  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

Chemotherapy; Drug resistance; Hypoxia; Solid tumor

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; PLATELET DERIVED GROWTH FACTOR; TIRAPAZAMINE; VASCULOTROPIN;

ANAEROBIC BACTERIUM; APOPTOSIS; BACTERIAL SPORE; BRONCHUS CANCER; CANCER CHEMOTHERAPY; CELL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG PENETRATION; GENE EXPRESSION; HUMAN; HYPOXIA; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOLID TUMOR; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH;

CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; PRODRUGS;

EID: 45949093096     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0637     Document Type: Review

References (40)

1. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia-inducible factor-2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006 ; 24 : 727-35.
2. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002 ; 20 : 680-7.
3. Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 2007 ; 67 : 7646-53.
4. Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumors. Br J Cancer 1995 ; 71 : 1210-3.
5. Cairns RA, Hill RP. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 2004 ; 64 : 2054-61.
6. Clottes E. Le facteur induit par l'hypoxie HIF-1 : régulation, implication dans la carcinogenèse et cible thérapeutique anticancer. Bull Cancer 2005 ; 92 : 119-27.
7. Brahimi-Horn C, Pouysségur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006 ; 93 : E73-E80.
8. Simon JM. Hypoxie et angiogenèse. Bull Cancer 2007 ; 94 : S160-S165.
9. Lauzier MC, Michaud MD, Déry MA, Richard DE. HIF-1 activation during tumor progression : implications and consequences. Bull Cancer 2006 ; 93 : 349-56.
10. Jain RK. Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy. Science 2005 ; 307 : 58-62.
11. Minchinton AI, Tannock IF. Drug penetration in solid tumors. Nat Rev Cancer 2006 ; 6 : 583-92.
12. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007 ; 99 : 1441-54.
13. Hill RP, Fyles W, Milosevic M, Pintilie M, Tsang RW. Is there a relationship between repopulation and hypoxia/reoxygenation? Results from human carcinoma of the cervix. Int J Radiat Biol 2003 ; 79 : 487-94.
14. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004 ; 4 : 806-13.
15. Trédan O, Lalani AS, Garbens AB, Tannock IF. The hypoxia-activated prodrug, AQ4N, penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Proc Amer Assoc Cancer Res 2007 ; (abstract5736).
16. Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004 ; 64 : 6537-41.
17. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002 ; 62 : 3387-94.
18. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996 ; 379 : 88-91.
19. Lotz C, Kelleher DK, Gassner B, Gekle M, Vaupel P, Thews O. Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells. Oncol Rep 2007 ; 17 : 239-44.
20. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003 ; 22 : 3213-20.
21. Muir CP, Adams MA, Graham CH. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Res Treat 2006 ; 96 : 169-76.
22. Haffty BG, Son YH, Papac R, Sasaki CT, Weissberg JB, Fischer D, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck : results of the Yale Mitomycin Randomized Trials. J Clin Oncol 1997 ; 15 : 268-76.
23. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson A, Denny W, et al. A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors. Proc Am Soc Clin Oncol 2007 ; (abstract 3516).
24. Williamson SK, Crowley JJ, Lara Jr. PN, McCoy J, Lau DH, Tucker RW, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer : Southwest Oncology Group Trial S0003. J Clin Oncol 2005 ; 23 : 9097-104.
25. Steward W, Middleton M, Benghiat A, Loadman P, Hayward C, Waller S, et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. Ann Oncol 2007 ; 18 : 1098-103.
26. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001 ; 98 : 15155-60.
27. Cheong I, Huang X, Bettegowda C, Diaz Jr. LA, Kinzler KW, Zhou S, et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006 ; 314 : 1308-11.
28. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000 ; 7 : 255-62.
29. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia-inducible factor-1. Mol Pharmacol 2006 ; 69 : 411-8.
30. Blackwell KL, Chi J, Sidor C, Burke P, LaVallee T, Shaw HS, et al. The effect of paclitaxel and 2-methoxyestradiol on tumor oxygenation and HIF-1α in breast cancer. Proc Am Soc Clin Oncol 2007 ; (abstract 3517).
31. Melillo G. Inhibiting hypoxia-inducible factor-1 for cancer therapy. Mol Cancer Res 2006 ; 4 : 601-5.
32. Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol 2002 ; 137 : 701-9.
33. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport : a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 2003 ; 63 : 5970-7.
34. Cárdenas-Navia LI, Secomb TW, Dewhirst MW. Effects of fluctuating oxygenation on tirapazamine efficacy : theoretical predictions. Int J Radiat Oncol Biol Phys 2007 ; 67 : 581-6.
35. Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006 ; 98 : 1118-28.
36. Lévesque JP, Winkler IG, Hendy J, Williams B, Helwani F, Barbier V, et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased HIF-1 alpha and VEGF-A in bone marrow. Stem Cells 2007 ; 25 : 1954-65.
37. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007 ; 104 : 5431-6.
38. Gray MD, Mann M, Nitiss JL, Hendershot LM. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase II alpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs. Mol Pharmacol 2005 ; 68 : 1699-707.
39. Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, et al. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine : a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006 ; 66 : 1664-74.
40. Cairns RA, Papandreou I, Sutphin PD, Denko NC. Metabolic targeting of hypoxia and HIF-1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 2007 ; 104 : 9445-50.